comparemela.com
Home
Live Updates
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate : comparemela.com
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New...
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Norbert Bischofberger ,
Sarah Connors ,
Jorge Dimartino ,
Kronos Bio ,
Christopher Dinsmore ,
Kronos Bio Inc ,
Corporate Affairs ,
Business Development ,
Exchange Commission ,
Nasdaq ,
Company On Linkedin ,
Jerome Lipper Multiple Myeloma Center ,
Dana Farber Cancer ,
San Mateo ,
Private Securities Litigation Reform Act ,
Quarterly Report ,
Investor Relations ,
Markets ,
comparemela.com © 2020. All Rights Reserved.